Clik here to view.
Analysts: Tiffany & Co. Is a Buy and 3 Other Research Notes to Look At
Tiffany & Co. (NYSE:TIF): Sterne Agee upgraded Tiffany & Co. to Buy from Neutral and put a $86 price target on the shares, citing the recent pullback in shares, gross margin expansion, and...
View ArticleClik here to view.
Analysts: Expedia Faces Intense Competition and 3 Other Research Notes to...
Expedia (NASDAQ:EXPE): Deutsche Bank downgraded Expedia to Hold from Buy, citing recent management changes at Hotels.com and the firm’s quarterly checks that indicate the company continues to face...
View ArticleClik here to view.
Analysts: Pandora Keeps Lead in Internet Radio and 3 More Research Notes to...
Pandora Media Inc. (NYSE:P): Canaccord’s survey indicates 92 percent of Apple’s (NASDAQ:AAPL) iTunes Radio listeners still use Pandora, indicating Pandora’s October metrics are unlikely to be impacted...
View ArticleClik here to view.
Analysts: LinkedIn Results ‘Solid’ and 3 More Research Notes to Check Out
LinkedIn Corp. (NYSE:LNKD): Piper Jaffray has raised its price target for LinkedIn to $285 from $270 after the company reported “solid” third-quarter results. The firm keeps an Overweight rating on...
View ArticleClik here to view.
Jim Cramer: Buy Disney, GameStop, and Gilead, But Sell This Stock
Jim Cramer made the following calls on November 8th, 2013. What do you think about his picks? Walt Disney Co. (NYSE:DIS): Jim Cramer ranked this stock a Buy. Cramer previously ranked this stock a Buy...
View ArticleClik here to view.
Jim Cramer: Buy Columbia Banking, Cheniere Energy Partners, and These 2 Stocks
Jim Cramer made the following calls on November 11th, 2013. What do you think about his picks? Columbia Banking System Inc. (NASDAQ:COLB): Jim Cramer ranked this stock a Buy. The stock’s 52-week high...
View ArticleClik here to view.
Analysts: BioMarin Will Trade Up on Panel Vote and 3 More Research Notes to...
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN): Citigroup expects that shares of BioMarin will trade up to the low $70 range following Tuesday’s positive Food and Drug Administration panel vote on Vimizim...
View ArticleClik here to view.
Gilead’s Sovaldi Awarded Breakthrough Designation
A number of drugs currently in development were approved for a “breakthrough therapy” designation from the Food and Drug Administration this past year, with Gilead Sciences’ (NASDAQ:GILD) Sovaldi, a...
View ArticleClik here to view.
Can Merck, Bristol-Myers, or AbbVie Compete with Gilead’s Cure for Hepatitis C?
Source: Thinkstock The race for a hepatitis C cure is closing in fast; Bristol-Myers Squibb Co. (NYSE:BMY) and Merck & Co. Inc. (NYSE:MRK) both announced Thursday that clinical trials of their...
View ArticleClik here to view.
From Sports to Fantasy to Literature: 10 Books Coming Out in October
From memoir to fantasy to literary fiction to current events, here are 10 of the biggest books coming out this month. Source: CBS Choose Your Own Autobiography, Neil Patrick Harris Neil Patrick Harris...
View Article
